Moderna, Inc.

Moderna is the mRNA biotech whose COVID revenue collapsed but whose pipeline — flu, cancer, respiratory — is now the whole reason to own the equity. The stock has doubled off the lows this year on pipeline enthusiasm, and July 31 is where that has to translate to guidance.

What the picture looks like:

• The economics are still under water: gross margin is negative (COGS exceeds revenue) and operating margin sits at negative 153% — meaning every quarter is a cash draw against the pipeline, and pipeline advances are the only path back to margin.
• The bounce is real but not fundamental: up 112% year-to-date and 46% above the 200-day, but the price sits at only 65% of the 52-week range — the recovery is early, and it is not a technical breakout yet.
• Insider signal is neutral-to-mild-sell: Chief Medical Officer Stephen Hoge sold $3.6M this week — small in absolute terms but pointed given the stock's bounce, meaning execs are not adding conviction into the pipeline setup.
• The category headwind is real: patient preference for standard flu vaccines is a $4.8B structural cap on the near-term mRNA-flu opportunity, meaning the pipeline story has to lean on cancer or respiratory reads, not flu volume.

July 31 earnings is the trigger. A guidance update on cash burn plus a specific pipeline data-readout timeline extends the recovery; another quarter of pipeline delays reads as the bounce fading and the tape retesting recent support.